Top

Published in:

01-03-2006 | Original article

Hydroxyurea responses and fetal hemoglobin induction in β-thalassemia/HbE patients’ peripheral blood erythroid cell culture

Authors: Ramida Watanapokasin, Duangmanee Sanmund, Pranee Winichagoon, Koichiro Muta, Suthat Fucharoen

Published in: Annals of Hematology | Issue 3/2006

Abstract

Due to genetic heterogeneity of β-thalassemia (β-thal) patients, several efforts have been undertaken to determine the efficacy of hydroxyurea treatment. The aim of this work is to determine the responder and nonresponder for hydroxyurea treatment in β-thal intermedia based on γ-globin mRNA and fetal hemoglobin (HbF) induction in human erythroid progenitor cells purified from a patient’s peripheral blood. Eighteen β-thal/hemoglobin E patients [13 β^E/codon41/42(-TCTT), 4 β^E/codon17, and 1 β^E/IVS-654], requiring blood transfusion occasionally, with Hb levels of 5.20–8.50 g/dl were studied. The relative levels of γ-globin mRNA was measured by real-time reverse-transcription polymerase chain reaction and HbF by high-performance liquid chromatography. The results indicated that erythroid progenitor cells treated with 30 μmol/l hydroxyurea for 96 h preferentially enhanced ^Gγ-and ^Aγ-globin mRNA. The mean values of ^Gγ-globin mRNA fold induction were higher than ^Aγ-globin mRNA (12±4 vs 4±0.30), the Pearson’s correlation of ^Gγ-and ^Aγ-globin mRNA was r=0.80. Induction of ^Gγ/^Aγ globin mRNA is up to ninefold. A 30% increase in the proportion of HbF out of the total Hb was found in cultures derived from four patients, 20–30% in cultures from nine patients, and less than 20% in cultures from five patients. In cultures from only two patients, increase in the proportion of HbF was less than 3%, and ^Gγ/^Aγ globin mRNA is less than 0.50.

Higgs DR, Thein SL, Woods WG (2001) The physiology of the thalassemia. In: Weatherall DJ, Clegg B (eds) The Thalassemia Syndromes, 4th ed. Blackwell Science Ltd, Oxford, pp 265–284

Weatherall DJ (2001) The thalassemias. In: Stamatoyannopoulos G, Majerus PW, Perimutter RM, Varmus.H (eds) The molecular basis for blood disorders, WB Saunders, Philadelphia PA, pp 183–226

Charache S, Terrin ML, Moore RD et al (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332:1317–1322PubMedCrossRef

Fucharoen S, Siritanaratakul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP (1996) Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E diseases. Blood 87:887–892PubMed

Fucharoen S, Winichagoon P, Wisedpanichkij R, Sae-Ngow B, Sripanich R, Oncoung W, Muangsapaya W, Chowthaworn J, Kanokpongsakdi S, Bunyaratvej A, Piankijagum A, Dewaele C (1998) Prenatal diagnoses of thalassemias and hemoglobinopathies by HPLC. Clin Chem 44:740–748PubMed

Maier-Redeiersperger M, De Montalembert M, Flahault A et al (1998) Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. Blood 91:4472–4479

Rodgers GP, Sauntharajah Y (2001) Advances in experimental treatment of beta thalassemia. Exp Opin Invest Drugs 10:925–934CrossRef

Fibach E, Burke LP, Schechter AN, Nogusi CT, Rodgers GP (1993) Hydroxyurea increases fetal hemoglobin in cultured erythroid cellsderived from normal individuals and patients with sickle cell anemia. Blood 81:1630–1635PubMed

Aker M, Dover G, Schrier S, Rachmilewitz EA (1995) Combination of erythropoietin and hydroxyurea results in improved quality and quantity of RBC in 7 patients with thalassemia intermedia. In: Beuzard Y, Lubin B, Rosa J (eds) Sickle cell disease and thalassemias: new trends in therapy, John Libbey Eurotext, London, pp 197

10.

Huang S-Z, Ren Z-R, Chen M-J, Xu H-P, Zeng Y-T, Rodgers GP (1994) Treatment of β-thalassemia with hydroxyurea (HU)-Effects of HU on globin gene expression. Sci China B 37:1350–1359PubMed

11.

Chang SS, Boehm CD, Higgs DR, Cutting GR (2000) Single -tube multiplex-PCR screen for common determinants of β-thalassemia. Blood 95:360–362

12.

Winichagoon P, Saechan V, Sripanich R, Nopparatana C, Kanokpongsakdi S, Maggio A, Fucharoen S (1999) Prenatal diagnosis of β-thalassemia by reverse dot blot hybridizaion. Prenatal Diag 19:428–435PubMedCrossRef

13.

Choi I, Muta K, Wickrema A, Krantz SB, Nishimura J, Nawata H (2000) Interferon gamma delays apoptosis of mature erythroid progenitor cells in the absence of erythropoietin. Blood 95:3742–3749PubMed

14.

Matsushima T, Nakashima M, Oshima K, Abe Y, Nishimura J, Nawata H, Watanabe T, Muta K (2001) Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells. Blood 98:313–321PubMedCrossRef

15.

Sawada K, Krantz SB, Kans JS, Dessypris EN, Sawyer S, Glick AD, Civin CI (1987) Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin. J Clin Invest 80:357–366PubMedCrossRef

16.

Muta K, Krantz SB (1993) Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin like growth factor I as well as erythropoietin. J Cell Physiol 156:264–271PubMedCrossRef

17.

Sui X, Krantz SB, Zhao Z (1997) Identification of increased protein tyrosine phosphatase activity in polycythemia vera erythroid progenitor cells. Blood 90:651–657PubMed

18.

Sui X, Krantz SB, Zhao Z (2000) Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signalling pathways. Br J Haematol 110:63–70PubMedCrossRef

19.

Dover GJ, Boyer SH (1980) Quantitation of hemoglobins within individual red cells: asynchronous biosynthesis of fetal and adult hemoglobin during erythroid maturation in normal subjects. Blood 56:1082–1091PubMed

20.

Wood WG, Jones RW (1981) Erythropoiesis and hemoglobin production: a unifying model involving sequential gene activation. In: Stamatoyannopoulos G, Nienhuis AW (eds) Hemoglobins and Development in Differentiation, Alan R Liss Inc, New York, pp 243–261

21.

Papayannopoulou Th, Kalmantis T, Stamatoyannopoulos G (1979) Cellular regulation of hemoglobin switching: evidence for inverse relationship between fetal hemoglobin synthesis and degree of maturity of human erythroid cells. Proc Natl Acad Sci USA 76:6420–6424PubMedCrossRef

22.

Chomczynski P (1993)A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15:532–537PubMed

23.

Watanapokasin Y, Winichagoon P, Fucharoen S, Wilairat P (2000) Relative quantitation of mRNA in β-thalassemia/HbE using real-time polymerase chain reaction. Hemoglobin 4:105–116

24.

Winichagoon P, Fucharoen S, Wilairat P, Cihara K, Fukumaku Y (1995) Role of alternatively spliced beta E-globin mRNA on clinical severity of beta-thalassemia/hemoglobin E disease. Southeast Asian J Trop Med Public Health 26(S1):241–245PubMed

25.

Winichagoon P., Fucharoen S, Chen P, Wasi P (2000) Genetic Factors Affecting Clinical Severity in Thalassemia Syndromes. J Pediatr Hematol Oncol 22:573–580PubMedCrossRef

26.

Fibach E, Manor D, Oppenheim A, Rachmilewitz EA (1989) Proliferation and maturation of human erythroid progenitors in liquid culture. Blood 73:100–103PubMed

27.

Fibach E, Manor D, Treves A, Rachmilewitz EA (1991) Growth of normal erythroid progenitors in liquid culture: a comparison with colony growth in semisolid culture. Int J Cell Cloning 9:57–64PubMedCrossRef

28.

Hopp C, Vichinsky E, Lewis B, Foote D, Styles L (1999) Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Hematol 62:221–227CrossRef

29.

Rodgers GP, Rachmilewitz EA (1995) Novel treatment options in the severe β-globin disorder. Br J Haematol 91:263–268PubMed

30.

Atweh GF, Sutton M, Nassif I, Boonsaild V, Dover GJ, Wallenstein S, Wright E, McMahon L, Stamatoyannopoulos G, Faller DV, Perrine SP (1999) Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 93:1790–1797PubMed

31.

Rodgers GP, Rachmilewitz EA (1995) Novel treatment options in the severe β-globin disorder. Br J Haematol 91:263–268PubMed

32.

Zeng YT, Huang SZ, Ren ZR, Lu ZH, Zeng FY, Schechter AN, Rodgers GP (1995) Hydroxyurea therapy in β-thalassemia intermedia: improvement in haematological parameters due enhanced β-globin synthesis. Br J Haematol 90:557–563PubMed

33.

Janes SM, Cunningham JM (1998) Understanding fetal globin gene expression: a step towards effective HbF reactivation in haemoglobinopathies. Br J Hematol 102:415–422CrossRef

34.

Smith RD, Constance JL, Noguchi T, Schechter AN (2000) Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. Blood 95:863–869PubMed

Title: Hydroxyurea responses and fetal hemoglobin induction in β-thalassemia/HbE patients’ peripheral blood erythroid cell culture
Authors: Ramida Watanapokasin
Duangmanee Sanmund
Pranee Winichagoon
Koichiro Muta
Suthat Fucharoen
Publication date: 01-03-2006
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 3/2006
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-005-0049-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hydroxyurea responses and fetal hemoglobin induction in β-thalassemia/HbE patients’ peripheral blood erythroid cell culture

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2006

Soluble c-kit ligand production by bone marrow stromal cells is independent of the degree of neutropenia in patients with chronic idiopathic neutropenia

Successful treatment of lymph node extramedullary plasmacytoma with bortezomib

Spontaneous tumor lysis syndrome in a patient with diffuse large B cell lymphoma and Richter syndrome

Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period

Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study

Cutaneous zygomycosis at catheter insertion site in AML-M4Eo

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page